Healthcare / Health Information ServicesHKSE
$2.63
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-163.8M · quality 21.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-323.4%
↓Gross Margin
40.7%
↓Debt/Equity
5.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+169.1%
FCF CAGR
—
FCF margin
-93.5%
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $220.0M · net income $-314.9M · FCF $-205.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $220.0M | $220.0M | $122.3M | $67.2M | $11.3M |
| Net Income | $-314.9M | $-314.9M | $-198.3M | $-359.1M | $-502.5M |
| EBITDA | $-266.1M | $-266.1M | $-149.4M | $-317.6M | $-470.8M |
| EPS | -0.27 | -0.27 | -0.22 | -0.40 | -0.40 |
| Gross Margin | 40.7% | 40.7% | 44.2% | 47.7% | 29.2% |
| Operating Margin | -113.5% | -113.5% | -140.8% | -225.4% | -923.9% |
| Net Margin | -143.1% | -143.1% | -162.1% | -534.3% | -4450.0% |
| Balance Sheet | |||||
| Debt/Equity | 5.81 | 5.81 | -0.84 | -1.10 | -0.30 |
| Current Ratio | 1.56 | 1.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-205.7M | $-205.7M | $-163.8M | $-155.0M | $-119.7M |
| Returns | |||||
| ROE | -323.4% | -323.4% | 42.8% | 108.1% | 45.9% |
| Valuation | |||||
| P/B | 31.77 | 31.77 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 79.9% | 79.9% | 82.0% | 495.2% | — |
| EPS Growth | -23.1% | -23.1% | 44.8% | -0.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.22 → -0.27
Residual
-61.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.